Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (September 2015)
28 slides from Matinas Biopharma's investor presentation, Sep 9, 2015
Slide 1: Transforming the Way Potent Medicines for Infectious Diseases Are Designed
www.matinasbiopharma.com OTCQB: MTNB TRANSFORMING THE WAY POTENT MEDICINES FOR INFECTIOUS DISEASES ARE DESIGNED Corporate Presentation September 2015
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other st
Slide 3: MTNB Overview
MTNB Overview • Proprietary, NIH - supported, lipid - crystal nano - encapsulation technology • Immediate focus on taking powerful, but sparingly used, anti - fungal and anti - bacterial drugs and increasing safety and potency • MAT2203, an oral formulation of Amphotericin B with key differentiating
Slide 4: Lead Therapeutic Pipeline
Discovery IND Preparation Phase 2 Development Phase 3 Development Lead Therapeutic Pipeline Gram - Negative Bacterial Infections Metabolic/Cardiovascular Development Programs Anti - Infective Development Programs Fungal Infections MAT2203 MAT2501 4 Actively seeking partnering opportunities
Slide 5: Antimicrobial Resistance is a Global Threat
Antimicrobial Resistance is a Global Threat “CDC sets threat levels for drug - resistant 'superbugs’” “Superbugs to kill 'more than cancer' by 2050” “WHO Calls for Action on Superbugs” “CDC sounds alarm on deadly, untreatable superbugs” 5
Slide 6: Government Incentives and NIH Support
Drug - resistance threat has led to strong government incentives and specific NIH support of MTNB technology ▪ Congressional initiatives: – GAIN: extra 5 - year exclusivity (passed) – ADAPT: accelerated antibiotic development pathway (pending) – DISARM: improved reimbursement and pricing for antibio
Slide 7: Limitations of Current Anti-Infective Therapy
Limitations of Current Anti - Infective Therapy THE PROBLEM • Insufficient coverage of Multidrug - resistant (MDR) fungal and bacterial infections • Significant safety and tolerability concerns • Lack of oral dosage forms to permit transition therapy THE DESIRED SOLUTION • Enormous unmet medical nee
Slide 8: Cochleate Technology Offers Significant Clinical Improvement Potential
Cochleate Technology Offers Significant Clinical Improvement Potential Development Work To Date • Efficacy demonstrated in - vivo (numerous animal studies) • Safety and tolerability demonstrated in Phase 1 human study Protects Organs • Cochleates act as a shield for the body from toxic drugs, signif
Slide 9: Cochleate Cell Delivery Mitigates the Limitations of Potent IV-Administered Anti-Infectives
Cochleate Cell Delivery Mitigates the Limitations of Potent IV - Administered Anti - Infectives 50 - 500 nm * Phosphatidylserine PS* Bilayer Calcium Drug 1. Reduces toxicity by containing drug inside particle 2. Size and surface features facilitate targeted delivery 3. O ral administration Low Calci
Slide 10: MAT2203 Amphotericin B Delivered in a Lipid-Crystal Nano-Particle Cochleate Formulation
MAT2203 Amphotericin B Delivered in a Lipid - Crystal Nano - Particle Cochleate Formulation -- Broad - Spectrum Fungicidal Agent -- 10
Slide 11: MAT2203 Represents Groundbreaking Advancement in Anti-Fungal Treatment
MAT2203 Represents Groundbreaking Advancement in Anti - Fungal Treatment • Amphotericin B is the antifungal of choice for immunocompromised patients • Pluses: Effective killing - agent (fungicidal), no observed clinical resistance in 50+ years of use. • Minuses: Significant toxicity, including high
Slide 12: Targeted Therapy – Efficacy at a Lower Dose
Control Existing AmB (IV, 1mg/kg) Existing AmB (IV, 2mg/kg) AmB Cochleates (Oral, 0.5 mg/kg ) Source: PHRI/Rutgers Studies in MAT2203 IND 12 Targeted Therapy – Efficacy at a Lower Dose Survival % Days 0% 20% 40% 60% 80% 100% ▪ Invasive Candidiasis mouse model at PHRI ▪ Oral delivery of en - cochleat
Slide 13: MAT2203: Significantly Lower Degree of Toxicity
13 MAT2203: Significantly Lower Degree of Toxicity 0 10 20 30 40 50 60 70 80 90 100 Fungizone Tox. Fungizone Eff. Ambisome Tox. Ambisome Eff. MAT2203 Tox. MAT2203 Eff. Fungizone NOAEL - Dog NOAEL – Rat Dose: mg/kg Ambisome MAT2203 Source: Monographs Fungizone and Ambisome , MAT2203 Pre - Clinical St
Slide 14: Targeted Therapy: Drug Levels High in Infected Tissues
14 Targeted Therapy: Drug Levels High in Infected Tissues 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 Plasma Cmax Urine Lung Liver Kidney Detected Levels - g/gram Healthy Rats - 15 mg/kg, 28days Healthy Dogs - 15mg/kg, 28days Candida Infected Mice - 10 mg/kg, 15 days Candida MIC Source: MAT2203 IND pre
Slide 15: MAT2203: Significantly Improved Tissue Penetration Profile
15 MAT2203: Significantly Improved Tissue Penetration Profile 0.01 0.10 1.00 10.00 100.00 0 2 4 6 8 10 12 14 16 Treatment Day Ampho, ug /gram tissue CAMB, PO 10 mg /Kg, Liver Fung, IP, 2 mg /Kg Liver MAT2203, Oral Fungizone , IP injection Rapid Tissue Penetration Controlled Levels of Amphotericin B
Slide 16: MAT2203 – Clinical Development Overview
MAT2203 – Clinical Development Overview Discovery IND Preparation Phase 2 Development Phase 3 Development MAT2203 x Successfully completed a range of efficacy animal studies at NIH with C - Amphotericin B x Single - Dose Phase 1 study completed with favorable tolerability and no serious adverse even
Slide 17: MAT2501 Amikacin Delivered in a Lipid-Crystal Nano-Particle Cochleate Formulation
MAT2501 Amikacin Delivered in a Lipid - Crystal Nano - Particle Cochleate Formulation -- Gram - Negative Aminoglycoside Antibiotic -- 17
Slide 18: The Drug Resistant Antibiotic Market
The Drug Resistant Antibiotic Market • Widespread use of antibiotics ($41 billion worldwide per IMS) has resulted in rapid increase in bacterial infections that are resistant to multiple antibacterial agents • Gram - negative bacterial infections characterized as #1 unmet medical need by infectious
Slide 19: MAT2501 – Development Overview
MAT2501 – Development Overview MAT2501 C - Amikacin (broad spectrum aminoglycoside) Treating severe and hospital - acquired gram - negative bacterial infections Potential High - need Indications: • Pulmonary infections – Cystic Fibrosis and Non - Tuberculous Mycobacterium • Hospital acquired urinary
Slide 20: Cochleate Nanoparticle Delivery Has Broad Utility with Potential for Orphan Drug Applications
Cochleate Nanoparticle Delivery has Broad Utility with Potential for Orphan Drug Applications Collaborations In - Vitro Animal POC IND - Prep Human Studies Amphotericin B NIH / PHRI Amikacin NIH Vaccines Ibuprofen Atovaquone NIH Capreomycin NIH Meropenem NIH Anti - virals NIH Omega - 3 FA 20
Slide 21: Intellectual Property
Intellectual Property Cochleate Lipid Delivery Portfolio – Exclusive License from Rutgers University • 17 issued and > 20 pending U.S. and foreign patents - Company controls prosecution - 10 patents issued within past 3 years; Patent protection currently extends through 2027 - Pending applications c
Slide 22: Management Team
Management Team Strong development and commercialization track record Roelof Rongen Co - Founder, Chief Executive Officer, Director Jerome D. Jabbour , JD Co - Founder, Chief Business Officer & General Counsel Raphael J. Mannino Chief Technical Officer George Bobotas , PhD Co - Founder, Chief Scient
Slide 23: Board of Directors
Board of Directors Herbert Conrad Chairman of the Board James Scietta Director Adam Stern Director Stefano Ferrari Director 23
Slide 24: Building Prominent Scientific Advisory Board
Building Prominent Scientific Advisory Board Anti - Infectives J. Carl Craft, MD, Chair - Former Chief Scientific Officer for Medicines for Malaria Venture (MMV) - Former Venture Head at Abbott Laboratories Anti - Infective Development Group David S. Perlin , Ph.D. - Internationally renowned expert
Slide 25: Comps Indicate Anti-Infective Programs Should Bring Substantial Value Appreciation Potential
Comps indicate that these new anti - infective programs should bring substantial value appreciation potential to MTNB MAT2203 C - Amphotericin B Fungal Infections - Entering Phase 2a MAT2501 C - Amikacin Gram - Negative Bacterial Infections - IND toxicology stage ~$200 million [CDTX] Novel Echinocan
Slide 26: Matinas BioPharma – Financial Snapshot
Matinas BioPharma – Financial Snapshot OTCQB MTNB Share Price $.94 Market Cap ~$54 million Shares Outstanding ~57 million As of September 4, 2015 26
Slide 27: MTNB Investment Highlights
MTNB Investment Highlights • Proprietary, NIH - supported lipid - crystal nano - encapsulation technology with true platform potential • Initial focus on taking powerful, but sparingly used, anti - fungal and anti - bacterial drugs and increasing safety and potency • MAT2203, an oral formulation of
Slide 28: Transforming the Way Potent Medicines for Infectious Diseases Are Designed
www.matinasbiopharma.com OTCQB: MTNB TRANSFORMING THE WAY POTENT MEDICINES FOR INFECTIOUS DISEASES ARE DESIGNED Corporate Presentation September 2015
Matinas BioPharma Holdings — Investor Presentation (September 2015) on 6ix